Clinical trials: Controlled Hypertension
Hypertension
Sympathetic Mapping/ Ablation of Renal Nerves Trial
To evaluate the safety and efficacy of targeted renal sympathetic denervation using SyMapCath I® and SYMPIONEER S1® Stimulator/ Generator in patients with essential hypertension for at least 6 months of the disease history and…
- Trial name
- SMART (NCT02761811)
- Testing
- SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
- Where
- 15 sites in China
- Volunteers
- 220 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Hypertension
Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension
The Wave VI study is a, multicenter, prospective, double-blind, randomized, sham controlled feasibility study of the safety of renal denervation in patients with stage I and II hypertension who have an average office systolic…
- Trial name
- NCT02480517
- Testing
- Ultrasound
- Volunteers
- 60 people
- Sponsor
- Kona Medical Inc.
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution
The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKB-9778 ophthalmic solution (eye drops) administered for 7 days in adults.
- Trial name
- NCT04284514
- Testing
- AKB-9778 Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Aerpio Therapeutics
Hypertension
OptiZ: Real World Evidence Study
Hypertension, or high blood pressure, is a major cause of preventable illness and premature death, affecting millions in the UK. Despite effective treatments, many patients struggle to achieve adequate blood pressure control.
- Trial name
- NCT06745726
- Testing
- Zestril
- Where
- United Kingdom
- Sponsor
- Closed Loop Medicine
High Risk Cardiovascular Disease, Hypertension
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events.
- Conditions
- High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
- Trial name
- ZENITH (NCT07181109)
- Testing
- Zilebesiran
- Where
- 1,190 sites in United States, Argentina and 33 more
- Volunteers
- 11,000 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertension
A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)
The purpose of this study was to evaluate the magnitude and durations of the antihypertensive effects of losartan using ambulatory blood pressure monitoring (ABPM), and to evaluate the safety of losartan 50 and 100 mg doses…
- Trial name
- NCT00886600
- Testing
- losartan potassium, hydrochlorothiazide (HCTZ)
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension
The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and effectiveness of the EnligHTN™ Renal Denervation System in the treatment of subjects with drug-resistant uncontrolled hypertension.
- Trial name
- EnligHTN-IV (NCT01903187)
- Testing
- EnligHTN Renal Denervation
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Abbott Medical Devices
Pulmonary Arterial Hypertension
Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development…
- Trial name
- NCT05135000
- Testing
- LTP001
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT)
The HYIMPACT study (IMPACT of Nebilet® in Blood Pressure Control in Patients with Hypertension) is a multinational, multicenter, observational, prospective, longitudinal real-world evidence study designed to assess the…
- Trial name
- HYIMPACT (NCT06938516)
- Where
- 49 sites in Indonesia, Malaysia and 5 more
- Volunteers
- 4,537 people
- Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00868894
- Testing
- DE-104 medium concentration, DE-104 high concentration, 0.005% latanoprost
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Santen Inc.
Hypertension, Diabetes
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and…
- Conditions
- Hypertension, Diabetes, Proteinuria
- Trial name
- TANDEM (NCT00234871)
- Testing
- trandolapril/verapamil, Lotrel (amlodipine/benazepril)
- Volunteers
- 357 people
- Sponsor
- Abbott
Hypertension, Impaired Glucose Tolerance
Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate…
- Trial name
- NCT00847899
- Testing
- AR9281
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Arete Therapeutics
Essential Hypertension
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS
- Trial name
- NCT05503953
- Testing
- AGSAVI, AGLS
- Where
- South Korea
- Volunteers
- 318 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Hypertension
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
This study examines the efficacy and safety of the Fixed Dose combination BAY98-7106 (nifedipine plus candesartan) in patients with hypertension, who do not achieve adequate control of blood pressure with candesartane alone.
- Trial name
- NCT02047019
- Testing
- Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), Candesartan Cilexetil
- Where
- 8 sites in Italy
- Sponsor
- Bayer
High Blood Pressure (& [Essential Hypertension])
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult…
- Trial name
- NCT07448506
- Testing
- Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Essential Arterial Hypertension
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02521233
- Testing
- Candesartan + Chlorthalidone (8mg+12,5mg), Candesartan + Chlorthalidone (8 mg + 25 mg), losartan+hydrochlorothiazide
- Sponsor
- EMS
Obese
A Study of Distal Jejunal-release Dextrose in Obese Participants
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obese participants.
- Trial name
- NCT05385978
- Testing
- APHD-012, APHD-012P
- Where
- 9 sites in Georgia, Germany and 1 more
- Volunteers
- 150 people
- Sponsor
- Aphaia Pharma US LLC
Hypertension
Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes
A study comparing the antihypertensives Valsartan and Lisinporil when doses are in the morning and comparing a morning dose of Valsartan with an evening dose.
- Trial name
- NCT00241124
- Testing
- valsartan, lisinopril
- Where
- Germany
- Volunteers
- 1,099 people, healthy volunteers welcome
- Sponsor
- Novartis
Pulmonary Hypertension, Interstitial Lung Disease
A Study of Mosliciguat in PH-ILD
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
- Trial name
- PHocus (NCT06635850)
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 85 sites in United States, Argentina and 18 more
- Volunteers
- 135 people
- Sponsor
- Pulmovant, Inc.